Increased risk of psoriasis with terbinafine, itraconazole

Increased risk of psoriasis with terbinafine, itraconazole Reactions 1680, p11 - 2 Dec 2017 Increased risk of psoriasis with terbinafine, itraconazole There is an increased risk of psoriasis in patients who have been exposed to the antifungal agents terbinafine or itraconazole, according to Taiwanese researchers. Researchers from the National Taiwan University utilised data from the National Health Insurance Research Database to identify patients with onychomycosis who had experienced cases of incident psoriasis during 2004 and 2010. A total of 3831 such patients were identified, as well as an identical number of matched controls. Compared with the matched controls, patients who had developed psoriasis were significantly more likely to have used terbinafine (>59%) or itraconazole (>42%). After adjusting for potential confounders and cumulative duration of antifungal drug prescription, use of terbinafine or itraconazole was associated with an increased risk of incident psoriasis (odds ratio [OR] 1.33; 95% CI 1.15, 1.54), and this association was found to be even stronger with more recent exposure to these drugs (OR 2.96; 95% CI 2.25, 3.90). Furthermore, when the individual drug risks were assessed, it was found that the risk of psoriasis was higher for itraconazole users, versus terbinafine users. The researchers highlighted that "future prospective studies should investigate if terbinafine or itraconazole use induces de novo psoriasis or aggravates pre-existing psoriasis, and if [the] psoriasis risk is lower for terbinafine than for itraconazole". They also noted that at present, the mechanisms via which itraconazole or terbinafine may cause psoriasis remain unclear. Chiu HY, et al. Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study. Drug Safety : 6 Nov 2017. Available from: URL: article/10.1007/s40264-017-0614-2 803284959 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals

Increased risk of psoriasis with terbinafine, itraconazole

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial